Although the recent trials and meta-analyses revealed that the effects of SGLT2 inhibitors in HF patients on all-cause and CV mortality did not vary by sex, T2DM duration, or the presence of CV disease [57,58,59,60], this does not mean that all HF patients will receive benefits from SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.